Your browser is no longer supported. Please, upgrade your browser.
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)-0.40 Insider Own1.18% Shs Outstand314.43M Perf Week-2.43%
Market Cap40.58B Forward P/E11.18 EPS next Y16.44 Insider Trans0.00% Shs Float214.95M Perf Month60.46%
Income18.30M PEG- EPS next Q3.73 Inst Own11.00% Short Float2.21% Perf Quarter56.26%
Sales581.90M P/S69.73 EPS this Y107.10% Inst Trans11.84% Short Ratio2.00 Perf Half Y102.57%
Book/sh5.26 P/B34.93 EPS next Y-46.49% ROA1.10% Target Price137.88 Perf Year272.49%
Cash/sh7.36 P/C24.96 EPS next 5Y- ROE1.80% 52W Range45.08 - 213.15 Perf YTD125.36%
Dividend- P/FCF- EPS past 5Y- ROI4.90% 52W High-13.81% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin87.70% 52W Low307.52% ATR15.10
Employees1941 Current Ratio2.80 Sales Q/Q218.00% Oper. Margin-17.10% RSI (14)63.61 Volatility16.00% 8.57%
OptionableYes Debt/Eq0.17 EPS Q/Q237.30% Profit Margin3.20% Rel Volume1.87 Prev Close168.00
ShortableYes LT Debt/Eq0.17 EarningsMay 10 BMO Payout- Avg Volume2.38M Price183.71
Recom2.30 SMA2013.99% SMA5044.68% SMA20082.76% Volume4,442,405 Change9.35%
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
May-08-21 01:46PM  
May-07-21 07:40PM  
04:30PM  
04:27PM  
03:30PM  
03:28PM  
02:04PM  
01:54PM  
09:42AM  
08:55AM  
08:40AM  
08:18AM  
06:45AM  
06:45AM  
06:45AM  
05:24AM  
04:31AM  
May-06-21 11:00PM  
09:59PM  
01:54PM  
01:49PM  
11:37AM  
08:20AM  
06:58AM  
06:36AM  
06:30AM  
06:22AM  
02:29AM  
May-05-21 09:44PM  
06:37PM  
05:52PM  
03:41PM  
02:06PM  
12:44PM  
11:48AM  
11:14AM  
10:42AM  
May-04-21 08:00PM  
05:44PM  
04:59PM  
03:35PM  
03:25PM  
02:54PM  
02:02PM  
11:50AM  
11:26AM  
10:00AM  
09:22AM  
08:42AM  
07:02AM  
06:54AM  
06:52AM  
May-03-21 08:00PM  
05:36PM  
04:14PM  
02:32PM  
01:19PM  
01:03PM  
12:22PM  
11:14AM  
11:13AM  
09:34AM  
08:08AM  
07:34AM  
Apr-30-21 05:37PM  
04:25PM  
01:57PM  
01:46PM  
01:37PM  
01:33PM  
12:33PM  
11:25AM  
08:57AM  
07:58AM  
07:27AM  
07:00AM  
06:30AM  
06:14AM  
05:26AM  
04:12AM  
Apr-29-21 04:47PM  
04:17PM  
04:07PM  
02:50PM  
01:51PM  
01:24PM  
04:00AM  
02:49AM  
Apr-28-21 01:32PM  
12:11PM  
07:02AM  
06:35AM  
02:47AM  
Apr-27-21 08:00PM  
01:58PM  
01:15PM  
05:54AM  
04:59AM  
Apr-26-21 06:13PM  
01:31PM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.